Zoetis, Inc. (ZTS)
83.82
+0.86
(+1.04%)
USD |
NYSE |
Nov 13, 16:00
83.82
0.00 (0.00%)
After-Hours: 17:33
Zoetis Enterprise Value : 41.51B for Nov. 12, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 12, 2026 | 41.51B |
| November 11, 2026 | 41.35B |
| November 10, 2026 | 41.31B |
| November 09, 2026 | 41.25B |
| November 06, 2026 | 40.06B |
| November 05, 2026 | 41.16B |
| November 04, 2026 | 44.05B |
| November 03, 2026 | 41.52B |
| November 02, 2026 | 41.60B |
| October 30, 2026 | 40.19B |
| October 29, 2026 | 39.81B |
| October 28, 2026 | 39.41B |
| October 27, 2026 | 39.58B |
| October 26, 2026 | 40.70B |
| October 23, 2026 | 40.72B |
| October 22, 2026 | 41.12B |
| October 21, 2026 | 40.15B |
| October 20, 2026 | 40.32B |
| October 19, 2026 | 40.14B |
| October 16, 2026 | 40.05B |
| October 15, 2026 | 39.66B |
| October 14, 2026 | 38.38B |
| October 13, 2026 | 37.98B |
| October 12, 2026 | 38.53B |
| October 09, 2026 | 38.19B |
| Date | Value |
|---|---|
| October 08, 2026 | 37.48B |
| October 07, 2026 | 36.86B |
| October 06, 2026 | 36.77B |
| October 05, 2026 | 36.80B |
| October 02, 2026 | 36.10B |
| October 01, 2026 | 35.86B |
| September 30, 2026 | 36.16B |
| September 29, 2026 | 36.68B |
| September 28, 2026 | 37.15B |
| September 25, 2026 | 36.99B |
| September 24, 2026 | 36.66B |
| September 23, 2026 | 37.22B |
| September 22, 2026 | 37.74B |
| September 21, 2026 | 37.10B |
| September 18, 2026 | 37.13B |
| September 17, 2026 | 37.80B |
| September 16, 2026 | 37.80B |
| September 15, 2026 | 37.97B |
| September 14, 2026 | 38.07B |
| September 11, 2026 | 37.78B |
| September 10, 2026 | 37.74B |
| September 09, 2026 | 37.92B |
| September 08, 2026 | 38.03B |
| September 04, 2026 | 38.96B |
| September 03, 2026 | 39.16B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Merck & Co., Inc. | 406.57B |
| Phibro Animal Health Corp. | 2.146B |
| Eli Lilly & Co. | 1.388T |
| Pfizer Inc. | 213.03B |
| Bristol Myers Squibb Co. | 159.61B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 591.00M |
| Revenue (Quarterly) | 2.391B |
| Total Expenses (Quarterly) | 1.80B |
| EPS Diluted (Quarterly) | 1.436 |
| Gross Profit Margin (Quarterly) | 69.51% |
| Profit Margin (Quarterly) | 24.72% |
| Earnings Yield | 7.02% |
| Operating Earnings Yield | 10.03% |
| Normalized Earnings Yield | 7.484 |